TY - JOUR
T1 - Increased plasma DYRK1A with aging may protect against neurodegenerative diseases
AU - Delabar, Jean M.
AU - Lagarde, Julien
AU - Fructuoso, Marta
AU - Mohammad, Ammara
AU - Bottlaender, Michel
AU - Doran, Eric
AU - Lott, Ira
AU - Rivals, Isabelle
AU - Schmitt, Frederic A.
AU - Head, Elizabeth
AU - Sarazin, Marie
AU - Potier, Marie Claude
N1 - Publisher Copyright:
© 2023, The Author(s).
PY - 2023/12
Y1 - 2023/12
N2 - Early markers are needed for more effective prevention of Alzheimer’s disease. We previously showed that individuals with Alzheimer’s disease have decreased plasma DYRK1A levels compared to controls. We assessed DYRK1A in the plasma of cognitively healthy elderly volunteers, individuals with either Alzheimer’s disease (AD), tauopathies or Down syndrome (DS), and in lymphoblastoids from individuals with DS. DYRK1A levels were inversely correlated with brain amyloid β burden in asymptomatic elderly individuals and AD patients. Low DYRK1A levels were also detected in patients with tauopathies. Individuals with DS had higher DYRK1A levels than controls, although levels were lower in individuals with DS and with dementia. These data suggest that plasma DYRK1A levels could be used for early detection of at risk individuals of AD and for early detection of AD. We hypothesize that lack of increase of DYRK1A at middle age (40–50 years) could be a warning before the cognitive decline, reflecting increased risk for AD.
AB - Early markers are needed for more effective prevention of Alzheimer’s disease. We previously showed that individuals with Alzheimer’s disease have decreased plasma DYRK1A levels compared to controls. We assessed DYRK1A in the plasma of cognitively healthy elderly volunteers, individuals with either Alzheimer’s disease (AD), tauopathies or Down syndrome (DS), and in lymphoblastoids from individuals with DS. DYRK1A levels were inversely correlated with brain amyloid β burden in asymptomatic elderly individuals and AD patients. Low DYRK1A levels were also detected in patients with tauopathies. Individuals with DS had higher DYRK1A levels than controls, although levels were lower in individuals with DS and with dementia. These data suggest that plasma DYRK1A levels could be used for early detection of at risk individuals of AD and for early detection of AD. We hypothesize that lack of increase of DYRK1A at middle age (40–50 years) could be a warning before the cognitive decline, reflecting increased risk for AD.
UR - http://www.scopus.com/inward/record.url?scp=85151792238&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85151792238&partnerID=8YFLogxK
U2 - 10.1038/s41398-023-02419-0
DO - 10.1038/s41398-023-02419-0
M3 - Article
C2 - 37015911
AN - SCOPUS:85151792238
SN - 2158-3188
VL - 13
JO - Translational Psychiatry
JF - Translational Psychiatry
IS - 1
M1 - 111
ER -
